However, the ADVANCE study, a case-cohort investigation involving 3,865 patients with T2DM and cardiovascular diseases or risk factors, indicated that only interleukin-6 presented a statistical significance in predicting macrovascular events and mortality following adjustment for IL-6, CRP, and fibrinogen (45). This evidence concerns the gene IL6 and cardiovascular disorder.